Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study

Joanna M. Cain; P. Y. Liu; David E. Alberts; Holly H. Gallion; Leslie Laufman; Janet O'Sullivan; Geoffrey Weiss; John N. Bickers

doi:10.1007/BF01275473

Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study

Joanna M. Cain, P. Y. Liu, David E. Alberts, Holly H. Gallion, Leslie Laufman, Janet O'Sullivan, Geoffrey Weiss, John N. Bickers

Cancer Center

Research output: Contribution to journal › Article

18 Scopus citations

Abstract

A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m². Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

Original language	English (US)
Pages (from-to)	23-24
Number of pages	2
Journal	Investigational New Drugs
Volume	10
Issue number	1
DOIs	https://doi.org/10.1007/BF01275473
State	Published - Mar 1 1992

Keywords

Didemnin-B
ovarian cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF01275473

Fingerprint Dive into the research topics of 'Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study'. Together they form a unique fingerprint.

Cite this

Cain, J. M., Liu, P. Y., Alberts, D. E., Gallion, H. H., Laufman, L., O'Sullivan, J., Weiss, G., & Bickers, J. N. (1992). Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study. Investigational New Drugs, 10(1), 23-24. https://doi.org/10.1007/BF01275473

@article{c87ac0115eb645539802828ec35380fc,

title = "Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study",

abstract = "A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.",

keywords = "Didemnin-B, ovarian cancer",

author = "Cain, {Joanna M.} and Liu, {P. Y.} and Alberts, {David E.} and Gallion, {Holly H.} and Leslie Laufman and Janet O'Sullivan and Geoffrey Weiss and Bickers, {John N.}",

year = "1992",

month = mar,

day = "1",

doi = "10.1007/BF01275473",

language = "English (US)",

volume = "10",

pages = "23--24",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study

AU - Cain, Joanna M.

AU - Liu, P. Y.

AU - Alberts, David E.

AU - Gallion, Holly H.

AU - Laufman, Leslie

AU - O'Sullivan, Janet

AU - Weiss, Geoffrey

AU - Bickers, John N.

PY - 1992/3/1

Y1 - 1992/3/1

N2 - A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

AB - A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

KW - Didemnin-B

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0026683370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026683370&partnerID=8YFLogxK

U2 - 10.1007/BF01275473

DO - 10.1007/BF01275473

M3 - Article

C2 - 1607250

AN - SCOPUS:0026683370

VL - 10

SP - 23

EP - 24

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -